BriaCell Therapeutics Corp. Warrant
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCTXZ research report →
Companywww.briacell.com
BriaCell Therapeutics Corp. , an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab.
- CEO
- William V. Williams
- IPO
- 2025
- Employees
- 16
- HQ
- West Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $150.70K
- P/E
- -0.25
- P/S
- 0.00
- P/B
- 0.35
- EV/EBITDA
- 0.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -221.75%
- ROIC
- -123.64%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-36,495,163 · -551603.14%
- EPS
- $-86.25 · -1915.19%
- Op Income
- $-37,733,686
- FCF YoY
- -14.59%
Performance & Tape
- 52W High
- $0.08
- 52W Low
- $0.08
- 50D MA
- $0.12
- 200D MA
- $0.23
- Beta
- 1.63
- Avg Volume
- 26.34K
Get TickerSpark's AI analysis on BCTXZ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BCTXZ Coverage
We haven't published any research on BCTXZ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCTXZ Report →